CRYOLIFE, INC. (NYSE:CRY) Files An 8-K Submission of Matters to a Vote of Security Holders

Item 5.07 Submission of Matters to a Vote of Security Holders.

At CryoLife, Inc.s (the Company or CryoLife) 2017 Annual Meeting
of Stockholders held on May 17, 2017 (the Annual Meeting),
CryoLifes stockholders elected each individual that was nominated
for election as director of the Company to serve until the next
annual meeting or until their successors are elected and have
been qualified. The stockholders also (i) approved, by
non-binding vote, the compensation paid to CryoLifes named
executive officers, as disclosed to Item 402 of Regulation S-K,
including the Compensation Discussion and Analysis, compensation
tables and narrative discussion, (ii) advised, by non-binding
vote, on the frequency of stockholder advisory votes on the
compensation of our named executive officers, (iii) approved
certain amendments to the CryoLife, Inc. Equity and Cash
Incentive Plan, and (iv) ratified the selection of Ernst Young
LLP as the independent registered public accounting firm for the
Company for the year ending December 31, 2017. The stockholders
did not approve a proposal to add three million shares to the
CryoLife, Inc. Equity and Cash Incentive Plan.

The final results of the voting on each matter of business at the
2017 Annual Meeting are as follows:

Election of Directors

Approval, by non-binding vote of the compensation paid to
CryoLifes named executive officers, as disclosed to Item 402 of
Regulation S-K, including the Compensation Discussion and
Analysis, compensation tables and narrative discussion.

Advisory vote on the frequency of stockholder advisory votes on
the compensation of our named executive officers.

In light of the voting results with respect to the interval at
which to seek shareholders approval of the compensation of the
named executive officers, the Company has determined, as was
recommended with respect to this proposal by the Companys board
of directors in the proxy statement for the 2017 annual meeting,
that the Company will hold future say on pay votes on an annual
basis until the occurrence of the next advisory vote on the
frequency of say on pay votes. The next advisory vote regarding
the frequency of say on pay votes is required to occur no later
than the Companys 2023 annual meeting of shareholders.

Approval of certain amendments to the CryoLife, Inc. Equity and
Cash Incentive Plan.

Approval of the addition of three million shares to the CryoLife,
Inc. Equity and Cash Incentive Plan.

Ratification of the selection of Ernst Young LLP as the
independent registered public accounting firm for the Company for
the year ending December 31, 2017.

About CRYOLIFE, INC. (NYSE:CRY)

CryoLife, Inc. (CryoLife) is engaged in medical device manufacturing and distribution, and in the processing and distribution of implantable human tissues for cardiac and vascular surgeries. The Company operates in two segments: Medical Devices and Preservation Services. The Medical Devices segment sells BioGlue, BioFoam, PerClot, CardioGenesis cardiac laser therapy, Hemodialysis Reliable Outflow (HeRO) Graft, and ProCol Vascular Bioprosthesis (ProCol). The Preservation Services segment preserves cardiac and vascular tissues. The Company’s surgical sealants and hemostats include BioGlue Surgical Adhesive (BioGlue), BioFoam Surgical Matrix (BioFoam), and PerClot, an absorbable powdered hemostat, which the Company distributes internationally for Starch Medical, Inc. (SMI). Its CardioGenesis cardiac laser therapy product line includes a laser console system and single-use, fiber-optic handpieces.

CRYOLIFE, INC. (NYSE:CRY) Recent Trading Information

CRYOLIFE, INC. (NYSE:CRY) closed its last trading session 00.00 at 18.35 with 97,388 shares trading hands.